A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Hepatitis B; Hepatitis C; Liver cancer
- Focus Adverse reactions
- Sponsors AstraZeneca; MedImmune
- 11 Dec 2017 Planned End Date changed from 20 Mar 2020 to 27 Dec 2019.
- 11 Dec 2017 Planned primary completion date changed from 20 Mar 2020 to 27 Dec 2019.
- 29 Aug 2017 Planned number of patients changed from 144 to 440.